Product Images Alendronate Sodium
View Photos of Packaging, Labels & Appearance
- arrow - image 1
- arrow - image 2
- Structural formula for Alendronate Sodium - image 3
- Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT (patients with radiographic vertebral fracture at baseline) - image 4
- Osteoporosis Treatment Studies in Postmenopausal Women Increase in BMD Alendronate Sodium 10 mg/day at Three Years - image 5
- Osteoporosis Treatment Studies in Postmenopausal Women Time Course of Effect of Alendronate Sodium 10 mg/day Versus Placebo: Lumbar Spine BMD Percent Change From Baseline - image 6
- Osteoporosis Prevention Studies in Postmenopausal Women - image 7
- Studies in Glucocorticoid - Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year - image 8
- Studies in Paget’s Disease of Bone Effect on Serum Alkaline Phosphatase of Alendronate Sodium 40 mg/day Versus Placebo or Etidronate 400 mg/day - image 9
- Label Image - lbl500901091
- Label Image - lbl500901095
Product Label Images
The following 11 images provide visual information about the product associated with Alendronate Sodium NDC 50090-1091 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
arrow - image 1
arrow - image 2
Structural formula for Alendronate Sodium - image 3
Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT (patients with radiographic vertebral fracture at baseline) - image 4
Osteoporosis Treatment Studies in Postmenopausal Women Increase in BMD Alendronate Sodium 10 mg/day at Three Years - image 5
Osteoporosis Treatment Studies in Postmenopausal Women Time Course of Effect of Alendronate Sodium 10 mg/day Versus Placebo: Lumbar Spine BMD Percent Change From Baseline - image 6
The text seems to be a table of bone mineral density (BMD) measurements from a multinational study, where different treatments or interventions (e.g. alendronate sodium at a dose of 10mg) were applied and the mean percentage change from baseline was reported. The table probably includes additional rows and columns that were not included in the provided text.*
Osteoporosis Prevention Studies in Postmenopausal Women - image 7
Studies in Glucocorticoid - Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year - image 8
Studies in Paget’s Disease of Bone Effect on Serum Alkaline Phosphatase of Alendronate Sodium 40 mg/day Versus Placebo or Etidronate 400 mg/day - image 9
Label Image - lbl500901091
Label Image - lbl500901095
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
